The burden of type 2 diabetes: strategies to prevent or delay onset

References

• American Diabetes AssociationStandards of medical care in diabetes- – 2006Diabetes Care200629Suppl 1S442
   Google Scholar
• AntelJGregoryPCNordheimUCB1 cannabinoid receptor antagonists for treatment of obesity and prevention of comorbid metabolic disordersJ Med Chem20064940081616821760
   PubMed Web of Science ®Google Scholar
• ArterburnDECranePKVeenstraDLThe efficacy and safety of sibutramine for weight loss: a systematic reviewArch Intern Med2004164994100315136309
   PubMed Web of Science ®Google Scholar
• BergAHSchererPEAdipose tissue, inflammation, and cardiovascular diseaseCirc Res2005969394915890981
   PubMed Web of Science ®Google Scholar
• BergmanAJStevensCZhouYPharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteersClin Ther200628557216490580
   PubMed Web of Science ®Google Scholar
• BoschJYusufSGersteinHCEffect of ramipril on the incidence of diabetesN Engl J Med200635515516216980380
   PubMed Web of Science ®Google Scholar
• BuchananTAXiangAHPetersRKPreservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic womenDiabetes200251279680312196473
   PubMed Web of Science ®Google Scholar
• BuseJBHenryRRHanJEffects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetesDiabetes Care20042726283515504997
   PubMed Web of Science ®Google Scholar
• CaglayanEBlaschkeFTakataYMetabolic syndrome-interdependence of the cardiovascular and metabolic pathwaysCurr Opin Pharmacol200551354215780821
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and PreventionNational diabetes fact sheet: general information and national estimates on diabetes in the United States, 20052005Atlanta, GAU.S. Department of Health and Human Services, Centers for Disease Control and Prevention
   Google Scholar
• Centers for Disease Control and PreventionDiabetes: Disabling, deadly, and on the rise2006U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Coordinating Center for Health Promotion
   Google Scholar
• ChandranMPhillipsSACiaraldiTAdiponectin: more than just another fat cell hormone?Diabetes Care20032624425012882876
   PubMed Web of Science ®Google Scholar
• ChiassonJLJosseRGGomisRAcarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trialLancet20023592072712086760
   PubMed Web of Science ®Google Scholar
• ChiquetteERamirezGDefronzoRA meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factorsArch Intern Med2004164209710415505122
   PubMed Web of Science ®Google Scholar
• De PetrocellisLCascioMGDiMVThe endocannabinoid system: a general view and latest additionsBr J Pharmacol20041417657414744801
   PubMed Web of Science ®Google Scholar
• DeedwaniaPCFonsecaVADiabetes, prediabetes, and cardiovascular risk: shifting the paradigmAm J Med20051189394716164876
   PubMed Web of Science ®Google Scholar
• DeFronzoRARatnerREHanJEffects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetesDiabetes Care200528109210015855572
   PubMed Web of Science ®Google Scholar
• DespresJPGolayASjostromLEffects of rimonabant on metabolic risk factors in overweight patients with dyslipidemiaN Engl J Med200535321213416291982
   PubMed Web of Science ®Google Scholar
• DespresJPLemieuxIAlmerasNContribution of CB1 blockade to the management of high-risk abdominal obesityInt J Obes (Lond)200630Suppl 1S44S5216570106
   PubMedGoogle Scholar
• Di MarzoVBifulcoMDe PetrocellisLThe endocannabinoid system and its therapeutic exploitationNat Rev Drug Discov200437718415340387
   PubMed Web of Science ®Google Scholar
• Di MarzoVGoparajuSKWangLLeptin-regulated endocannabinoids are involved in maintaining food intakeNature2001410822511298451
   PubMed Web of Science ®Google Scholar
• Diabetes Research Working GroupConquering diabetes. A strategic plan for the 21st century1999NIH Publication No. 99–4398. National Institutes of Health
   Google Scholar
• DruckerDJThe biology of incretin hormonesCell Metab200631536516517403
   PubMed Web of Science ®Google Scholar
• EckelRHKahnRRobertsonRMPreventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart AssociationCirculation20061132943616801475
   PubMed Web of Science ®Google Scholar
• GersteinHCYusufSBoschJEffect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trialLancet2006368109610516997664
   PubMed Web of Science ®Google Scholar
• GhanimHDhindsaSAljadaALow-dose rosiglitazone exerts an antiinflammatory effect with an increase in adiponectin independently of free fatty acid fall and insulin sensitization in obese type 2 diabeticsJ Clin Endocrinol Metab2006913553816804037
   PubMed Web of Science ®Google Scholar
• GlendeningPNHearneSASegalLMF as in fat: How obesity policies are failing in America. Trust for America’s Health2005 Available at: http://healthyamericans.org/reports/obesity2005/Obesity2005Report.pdf
   Google Scholar
• GoldsteinBJInsulin resistance: from benign to type 2 diabetes mellitusRev Cardiovasc Med20034Suppl 6S31014668698
   PubMedGoogle Scholar
• HaberEPXimenesHMProcopioJPleiotropic effects of fatty acids on pancreatic beta-cellsJ Cell Physiol200319411212447984
   PubMed Web of Science ®Google Scholar
• HamalainenHRonnemaaTVirtanenAImproved fibrinolysis by an intensive lifestyle intervention in subjects with impaired glucose tolerance. The Finnish Diabetes Prevention StudyDiabetologia20054822485316205886
   PubMed Web of Science ®Google Scholar
• HayashiTBoykoEJLeonettiDLVisceral adiposity and the risk of impaired glucose tolerance: a prospective study among Japanese AmericansDiabetes Care200326650512610016
   PubMed Web of Science ®Google Scholar
• HermanGABergmanAYiBTolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetesCurr Med Res Opin20062219394717022853
   PubMed Web of Science ®Google Scholar
• HermanGAStevensCVan DyckKPharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral dosesClin Pharmacol Ther2005786758816338283
   PubMed Web of Science ®Google Scholar
• HoganPDallTNikolovPEconomic costs of diabetes in the US in 2002Diabetes Care2003269173212610059
   PubMed Web of Science ®Google Scholar
• HuELiangPSpiegelmanBMAdipoQ is a novel adipose-specific gene dysregulated in obesityJ Biol Chem1996271106977038631877
   PubMed Web of Science ®Google Scholar
• Januvia™Januvia™ (sitagliptin) prescribing information. Merck & Co. Inc [online]2006 URL: http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf
   Google Scholar
• JohnBJIrukullaSAbulafiAMSystematic review: adipose tissue, obesity and gastrointestinal diseasesAliment Pharmacol Ther20062315112316696799
   PubMed Web of Science ®Google Scholar
• KadowakiTYamauchiTKubotaNAdiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndromeJ Clin Invest200611617849216823476
   PubMed Web of Science ®Google Scholar
• KendallDMRiddleMCRosenstockJEffects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylureaDiabetes Care20052810839115855571
   PubMed Web of Science ®Google Scholar
• KershawEEFlierJSAdipose tissue as an endocrine organJ Clin Endocrinol Metab20048925485615181022
   PubMed Web of Science ®Google Scholar
• KleinSSheardNFPi-SunyerXWeight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical NutritionDiabetes Care20042720677315277443
   PubMed Web of Science ®Google Scholar
• KnoblerHBenderlyMBoykoVAdiponectin and the development of diabetes in patients with coronary artery disease and impaired fasting glucoseEur J Endocrinol2006154879216381996
   PubMed Web of Science ®Google Scholar
• KnowlerWCBarrett-ConnorEFowlerSEReduction in the incidence of type 2 diabetes with lifestyle intervention or metforminN Engl J Med200234639340311832527
   PubMed Web of Science ®Google Scholar
• KnowlerWCHammanRFEdelsteinSLPrevention of type 2 diabetes with troglitazone in the Diabetes Prevention ProgramDiabetes2005541150615793255
   PubMed Web of Science ®Google Scholar
• KrakoffJFunahashiTStehouwerCDInflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima IndianDiabetes Care20032617455112766104
   PubMed Web of Science ®Google Scholar
• LebovitzHEAustinMMBlondeLACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendationsEndocr Pract200612Suppl 161216627372
   PubMedGoogle Scholar
• LehrkeMReillyMPMillingtonSCAn inflammatory cascade leading to hyperresistinemia in humansPLoS Med200411618
   Web of Science ®Google Scholar
• LewisGFCarpentierAAdeliKDisordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetesEndocr Rev2002232012911943743
   PubMed Web of Science ®Google Scholar
• LindsayRSFunahashiTHansonRLAdiponectin and development of type 2 diabetes in the Pima Indian populationLancet200236057812114044
   PubMed Web of Science ®Google Scholar
• MatsuzawaYTherapy Insight: adipocytokines in metabolic syndrome and related cardiovascular diseaseNat Clin Pract Cardiovasc Med20063354216391616
   PubMedGoogle Scholar
• Meridia®Meridia® (sibutramine hydrochloride monohydrate) prescribing information. Abbott Laboratories [online]2006 URL: http://rxabbott.com/pdf/meridia.pdf
   Google Scholar
• NataliAToschiEBaldewegSClustering of insulin resistance with vascular dysfunction and low-grade inflammation in type 2 diabetesDiabetes20065511334016567539
   PubMed Web of Science ®Google Scholar
• PanXRLiGWHuYHEffects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes StudyDiabetes Care199720537449096977
   PubMed Web of Science ®Google Scholar
• ParkHHasegawaGObayashiHRelationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertensionClin Chim Acta20063741293416857181
   PubMed Web of Science ®Google Scholar
• Pi-SunyerFXAronneLJHeshmatiHMEffect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trialJAMA20062957617516478899
   PubMed Web of Science ®Google Scholar
• PostonWSForeytJPSibutramine and the management of obesityExpert Opin Pharmacother200456334215013931
   PubMed Web of Science ®Google Scholar
• QiLDoriaAMansonJEAdiponectin genetic variability, plasma adiponectin, and cardiovascular risk in patients with type 2 diabetesDiabetes2006551512616644713
   PubMed Web of Science ®Google Scholar
• RazIEldorRCerneaSDiabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storageDiabetes Metab Res Rev20052131415386813
   PubMed Web of Science ®Google Scholar
• ReavenGMLithellHLandsbergLHypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal systemN Engl J Med1996334374818538710
   PubMed Web of Science ®Google Scholar
• RosenstockJThe potential of rimonabant in prediabetes: Pooled 1-year results from the RIO-Lipids, RIO-Europe and RIO-North American studies [abstract]2005Presented at the 65th Annual Meeting of the American Diabetes Association Abstract 13-LB
   Google Scholar
• SamahaFFEffect of very high-fat diets on body weight, lipoproteins, and glycemic status in the obeseCurr Atheroscler Rep200574122016255998
   PubMedGoogle Scholar
• SamahaFFIqbalNSeshadriPA low-carbohydrate as compared with a low-fat diet in severe obesityN Engl J Med200334820748112761364
   PubMed Web of Science ®Google Scholar
• SamahaFFSzaparyPOIqbalNEffects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndromeArterioscler Thromb Vasc Biol2006266243016357312
   PubMed Web of Science ®Google Scholar
• ScheenAFinerNHollanderPRimonabant improves cardiometabolic risk factors in overweight/obese patients with type 2 diabetes irrespective of background oral antidiabetic therapy (metformin or sulfonylureas) [abstract]Diabetes200655Suppl 1A1334 Abstract 560-P
   Google Scholar
• ScheenAJRenin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trialsDiabetes Metab2004a304879615671918
   PubMed Web of Science ®Google Scholar
• ScheenAJRenin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanismsDiabetes Metab2004b3049850515671919
   PubMed Web of Science ®Google Scholar
• SchererPEWilliamsSFoglianoMA novel serum protein similar to C1q, produced exclusively in adipocytesJ Biol Chem19952702674697592907
   PubMed Web of Science ®Google Scholar
• SchulzeMBRimmEBShaiIRelationship between adiponectin and glycemic control, blood lipids, and inflammatory markers in men with type 2 diabetesDiabetes Care2004271680715220246
   PubMed Web of Science ®Google Scholar
• SchulzeMBShaiIRimmEBAdiponectin and future coronary heart disease events among men with type 2 diabetesDiabetes200554534915677512
   PubMed Web of Science ®Google Scholar
• SeshadriPIqbalNSternLA randomized study comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and C-reactive protein levels in patients with severe obesityAm J Med200411739840515380496
   PubMed Web of Science ®Google Scholar
• SharmaAMThe obese patient with diabetes mellitus: from research targets to treatment optionsAm J Med2006119S172316563943
   PubMed Web of Science ®Google Scholar
• SharmaAMJankeJGorzelniakKAngiotensin blockade prevents type 2 diabetes by formation of fat cellsHypertension2002406091112411451
   PubMed Web of Science ®Google Scholar
• SherwinRSAndersonRMBuseJBThe prevention or delay of type 2 diabetesDiabetes Care200326Suppl 1S62912502620
   PubMed Web of Science ®Google Scholar
• SprangerJKrokeAMohligMAdiponectin and protection against type 2 diabetes mellitusLancet2003361226812547549
   PubMed Web of Science ®Google Scholar
• SternLIqbalNSeshadriPThe effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: one-year follow-up of a randomized trialAnn Intern Med20041407788515148064
   PubMed Web of Science ®Google Scholar
• StoffersDADesaiBMDeLeonDDNeonatal exendin-4 prevents the development of diabetes in the intrauterine growth retarded ratDiabetes2003527344012606515
   PubMed Web of Science ®Google Scholar
• SzaparyPOBloedonLTSamahaFFEffects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndromeArterioscler Thromb Vasc Biol200626182816284192
   PubMed Web of Science ®Google Scholar
• TorgersonJSHauptmanJBoldrinMNXENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patientsDiabetes Care2004271556114693982
   PubMed Web of Science ®Google Scholar
• TuomilehtoJLindstromJErikssonJGPrevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose toleranceN Engl J Med200134413435011333990
   PubMed Web of Science ®Google Scholar
• US National Institutes of HealthClinicalTrials.gov. 2006. [online] Accessed 17 October 2006. URL: http://www.clinicaltrials.gov/ct/show/NCT00325650;jsessionid=DE34C9537828718F3BB395432F702959?order=4
   Google Scholar
• UusitupaMLindiVLouherantaALong-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention StudyDiabetes2003522532814514637
   PubMed Web of Science ®Google Scholar
• Van GaalLFRissanenAMScheenAJEffects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe studyLancet200536513899715836887
   PubMed Web of Science ®Google Scholar
• VettorRSerraRFabrisREffect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studiesDiabetes Care200528942915793204
   PubMed Web of Science ®Google Scholar
• VijanSStuartNSFitzgeraldJTBarriers to following dietary recommendations in Type 2 diabetesDiabet Med20052232815606688
   PubMed Web of Science ®Google Scholar
• WangQBrubakerPLGlucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db miceDiabetologia20024512637312242459
   PubMed Web of Science ®Google Scholar
• WeyerCFunahashiTTanakaSHypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemiaJ Clin Endocrinol Metab2001861930511344187
   PubMed Web of Science ®Google Scholar
• WildSRoglicGGreenAGlobal prevalence of diabetes: estimates for the year 2000 and projections for 2030Diabetes Care20042710475315111519
   PubMed Web of Science ®Google Scholar
• WingRRHammanRFBrayGAAchieving weight and activity goals among diabetes prevention program lifestyle participantsObes Res20041214263415483207
   PubMedGoogle Scholar
• XuHBarnesGTYangQChronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistanceJ Clin Invest200311218213014679177
   PubMed Web of Science ®Google Scholar
• YachDStucklerDBrownellKDEpidemiologic and economic consequences of the global epidemics of obesity and diabetesNat Med20061262616397571
   PubMed Web of Science ®Google Scholar
• ZraikaSDunlopMProiettoJEffects of free fatty acids on insulin secretion in obesityObes Rev200231031212120417
   PubMedGoogle Scholar